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Summary
BACKGROUND: Amenable mortality is a composite mea-
sure of deaths from conditions that might be avoided by
timely and effective healthcare. It was developed as an in-
dicator to study health care quality.
METHODS: We calculated mortality rates for the popula-
tion aged 0–74 years for the time-period 1996–2010 and
the following groups of causes of death: amenable con-
ditions, ischaemic heart diseases (IHD, defined as part-
ly amenable) and remaining conditions. We compared the
Swiss results with those published for 16 other high-in-
come countries. To examine the association between
amenable mortality and socioeconomic position, we calcu-
lated hazard ratios (HRs) by using Cox regression.
RESULTS: Amenable mortality fell from 49.5 (95% confi-
dence interval [CI] 48.2–51.0) to 35.7 (34.6–36.9) in males
and from 55.0 (53.6–56.4) to 43.4 (42.2–44.6) per 100 000
person-years in females, when 1996–1998 was compared
with 2008–2010. IHD mortality declined from 64.7 (95%
CI 63.1–66.3) to 33.8 (32.8–34.8) in males and from 18.0
(17.2–18.7) to 8.5 (8.0–9.0) in females. However, between
1996–1998 and 2008–2010 the proportion of all-cause
mortality attributed to amenable causes remained stable
in both sexes (around 12% in males and 26% in females).
Compared with 16 other high-income countries, Switzer-
land had the lowest rates of amenable mortality and
ranked among the top five with the lowest ischaemic heart
disease mortality. HRs of amenable causes in the lowest
socioeconomic position quintile were 1.77 (95% CI
1.66–1.90) for males and 1.78 (1.47–2.16) for females
compared with 1.62 (1.58–1.66) and 1.38 (1.33–1.43) for
unamenable mortality. For ischaemic heart disease, HRs
in the lowest socioeconomic position quintile were 1.76
(95% CI 1.66–1.87) for males and 2.33 (2.07–2.62) for fe-
males.
CONCLUSIONS: Amenable mortality declined substan-
tially in Switzerland with comparably low death rates for
amenable causes. Similar to previous international stud-
ies, these Swiss results showed substantial socioeconom-
ic inequalities in amenable mortality. Proportions of
amenable mortality remained constant over time and pat-
terns of inequalities observed for amenable causes in men
did not substantially differ from those observed for non-
amenable causes of death. Additional amenable mortality
research is needed to better understand the factors con-
tributing to mortality changes and social inequalities in-
cluding information on disease characteristics and health
care supply measures.
Key words: amenable mortality, population health,
healthcare, cross-national comparison, socioeconomic in-
equalities, Switzerland
Background
A major goal of healthcare systems is to improve the health
of the population they serve. According to the definition
of the World Health Organization (WHO) Framework for
Health System Performance Assessment, population health
“should reflect the health of individuals throughout their
life course and include both premature mortality and
non-fatal health outcomes” [1]. Further, population health
“is concerned both with the average level of population
health and with health distribution inequalities within the
population” [1]. Decision makers need to regularly mon-
itor the performance of the healthcare system, including
subcomponents such as regions within the country [1].
This implies the need for core indicators suitable for as-
sessing the health systems performance.
Amenable mortality is an established concept used to mea-
sure the effectiveness of healthcare services by counting
premature deaths that should not have occurred in the
event of timely and appropriate medical care. The concept
has its origin in the idea of avoidable mortality introduced
in 1976 by David Rutstein and colleagues [2]. Avoidable
mortality consists of two components: (1) preventable
mortality, which can be avoided primarily through primary
prevention (e.g., lung cancer deaths through antismoking
campaigns), and (2) amenable mortality, which can be
avoided through timely and appropriate healthcare (e.g.,
breast cancer through early detection and high quality
treatment).
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Authors reviewing the literature on amenable mortality re-
ported large regional disparities, but consistent patterns in
time trends with a more rapid decline of amenable mor-
tality than all-cause and/or non-amenable mortality [3, 4].
There is also strong evidence that socially disadvantaged
groups have a higher risk of death from amenable causes
[3–8]. For example, Stirbu et al. (2010) [8] investigated
educational inequalities in amenable mortality in Europe
based on selected conditions of the original list of Rutstein
et al. [2]. Educational inequalities in amenable mortality
were found in all European countries studied and for all
conditions included. Inequalities were especially pro-
nounced for infectious diseases and conditions requiring
acute care [8]. The findings of Stirbu et al. are consistent
with earlier literature [4] and more recent studies [3, 6,
7, 9], despite heterogeneity in study design, indicators of
social status and lists of causes of death classified as
amenable.
Switzerland is a small country in Central Europe with
about 8.3 million inhabitants in a territory of less than
42 000 km2. The country performs well economically, with
the highest average household net financial wealth world-
wide [10]. Switzerland is a federal state composed of 26
cantons with far-reaching autonomy. Healthcare provision
is primarily the responsibility of cantons, and insurance
companies operate largely on a regional basis [11, 12]. The
current Swiss healthcare system is based on the Health In-
surance Law (LAMal) legislated in 1996 which (1) made
basic health insurance mandatory for all residents, (2) au-
thorised the Swiss federal government to define a cata-
logue of benefits that have to be covered by basic health
insurance, and (3) introduced competition between health
insurance companies through a risk adjustment scheme.
Mandatory insurance premiums have to be paid either by
the individual and/or the cantons and the state (persons el-
igible for health insurance subsidies). Before 1996, health
insurance was predominantly voluntary and basic benefit
packages varied substantially by insurance fund [12]. Now
Switzerland has universal basic health insurance coverage
and up to 90% of the insured population has supplemental
health insurance [13]. Healthcare in Switzerland is costly.
In 2012, Swiss health expenditures accounted for 11.4%
of its gross domestic product [11]. However, expenditures
alone say little about the effectiveness and quality of
healthcare systems. The United States healthcare system,
for example, is one of the most expensive in the world,
but consistently underperforms in comparisons with other
countries [14].
Data from Switzerland were included in previous interna-
tional publications on amenable mortality [7, 8, 15]. How-
ever, to the best of the authors’ knowledge, no detailed in-
vestigation of this topic for Switzerland exists. The main
objectives of this study were to examine: (1) time trends
in amenable mortality in Switzerland, (2) Swiss results in
an international context, and (3) Swiss-specific association
between sociodemographic characteristics and amenable
mortality.
Material and methods
Data sources and analytic variables
Mortality data and mid-year population estimates by
5-year age-bands (0–4, 5–9 … 85+ years), for all perma-
nent Swiss residents 1996–2010 were obtained from the
Swiss Federal Statistical Office (SFSO). The year 1996
was chosen as starting point because the definition of the
underlying cause of death deviated from international stan-
dards up to 1995, leading to substantial breaks in cause-
specific mortality trends [16, 17]. Further, in 1996 a major
health system reform came into force. All deaths included
in the study were coded by SFSO using the 10th revision of
the International Statistical Classification of Diseases and
Related Health Problems (ICD-10), in accordance with in-
ternational standards.
Data on age-standardised amenable mortality rates across
16 high-income countries other than Switzerland have
been taken from Nolte and McKee’s work published in
2011 (time period 1997–1998 and 2006–2007) [18]. They
used the WHO mortality database as their primary data
source. A detailed description of Nolte and McKee meth-
ods can be found elsewhere [18].
Data from the Swiss National Cohort (SNC) were used to
examine the association between sociodemographic char-
acteristics and amenable mortality. Ethical approval was
obtained for the Swiss National Cohort from the cantonal
ethics committees in Bern and Zurich. Given the anony-
mous nature of the data, no informed consent was required.
The SNC is a longitudinal study based on the Swiss nation-
al census of 1990 and 2000 linked to SFSO mortality data
and emigration records up to 2008. A detailed description
of the SNC can be found elsewhere [19, 20]. The pre-
sent analysis of the SNC is based on the linked 2000 cen-
sus with estimated population coverage of 98.6% [21, 22].
The dataset of the SNC is enhanced with an area-based in-
dex of Swiss socioeconomic position (Swiss-SEP). Swiss-
SEP is a composite area level measure including four do-
mains: income, education, occupation and housing condi-
tions [21]. Socioeconomic position was analysed with use
of quintiles of the Swiss-SEP index. Other SNC sociode-
mographic characteristics included nationality (Swiss ver-
sus non-Swiss) and language region of residence at time of
census (German, French or Italian). Nationality has been
added to the model because other Swiss studies reported
mortality disparities between Swiss and non-Swiss citizens
[23, 24]. Language region of residence is a common co-
variate in Swiss health-related analyses because of known
cultural differences between the regions that reflect the
countries bordering Switzerland. Further, there is evidence
for regional variations in risk factors and treatment regi-
mens [25, 26].
Definition of amenable mortality
In this study, we used the definition of amenable mortality
compiled by Nolte and McKee [4], which is based on an
annotated review and has been used by other researchers
[27–30]. Selection of causes of death considered amenable
to medical care was based on included conditions respon-
sive to medical interventions (secondary prevention or
medical treatment). The selected causes of death classified
as amenable are listed in table 1.
Nolte and McKee included ischaemic heart diseases (IHD)
in their list of amenable deaths, recommending that this
group be separately analysed because: (1) the extent of
avoidability remained unclear, (2) IHD could be under-
stood as indicator for healthcare as well as for health policy
and (3) the large proportion of deaths from IHD could
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obscure the contribution of other amenable causes [4]. In
later work, Nolte and McKee [18, 31] assigned 50% of
IHD deaths as amenable to healthcare services and includ-
ed them in the overall number of amenable deaths. The
change was based on accumulating evidence that up to half
of IHD deaths may be potentially amenable to healthcare.
Due to arguments (2) and (3) above, IHD was analysed
separately herein. Causes of death were categorised as: (1)
amenable conditions amenable to healthcare, (2) IHD and
(3) non-amenable causes derived from combining the re-
maining causes. With increased age, amenable deaths de-
crease and the specificity of death certificate cause of death
becomes less exact (e.g., high prevalence of multi-morbid-
ity). Therefore, like Nolte and McKee, we used an upper
age limit of 74 years with some exceptions (e.g., for child-
hood diseases, diabetes mellitus, leukaemia) [4, 31]. A de-
tailed justification for the selection of causes of death and
corresponding age limits is outlined in Nolte and McKee’s
2004 review [4].
Analytic methods
Mortality rates and corresponding 95% confidence inter-
vals (95% CIs) were calculated for the death categories
listed above using mortality data and mid-year population
estimates from the SFSO 1996–2010. All rates were cal-
culated as age-standardised mortality rates (ASMR) per
100 000 person-years (PY) for the age group 0–74 years,
by use of the direct method and the European standard
population as the reference population [32]. To minimise
the effect of random variation, mortality rates were calcu-
lated grouped by three calendar years.
For international comparisons, Swiss mortality rates were
calculated for the time periods 1997–1998 and 2006–2007,
corresponding to those published by Nolte and McKee
[18]. Unlike the present study, Nolte and McKee [18] did
not separate amenable causes and IHD. To standardise,
rates for amenable mortality and IHD mortality were recal-
culated to allow separate consideration of IHD deaths us-
ing the three categories specified above.
To estimate the association between amenable mortality
and demographic characteristics, we calculated hazard ra-
tios (HRs) and 95% CIs using Cox proportional hazard
models based on the SNC dataset. Included persons were
followed until death, 75th birthday, migration or 31 De-
cember 2008. Models included all SNC socioeconomic
and demographic variables specified above and were ad-
justed for age using age at date of census as time-scale
[33, 34]. To control for birth cohort and/or period effects,
the models were stratified into five-year birth cohorts, al-
lowing for different baseline hazards within each stratum
[33]. Of available SNC persons, 3.9% (males) and 3.3%
Table 1: Causes of death amenable to healthcare.
Name of group Age (years) ICD-10
1 Intestinal infections 0–14 A00–A09
2 Tuberculosis 0–74 A15–A19, B90
3 Other infections (diphtheria, tetanus, poliomyelitis) 0–74 A36, A35,A80
4 Whooping cough 0–14 A37
5 Septicaemia 0–74 A40–A41
6 Measles 1–14 B05
7 Malignant neoplasm of colon and rectum 0–74 C18–C21
8 Malignant neoplasm of skin 0–74 C44
9 Malignant neoplasm of breast 0–74 C50
10 Malignant neoplasm of cervix uteri 0–74 C53
11 Malignant neoplasm of cervix uteri and body of the uterus 0–44 C54, C55
12 Malignant neoplasm of testis 0–74 C62
13 Hodgkin’s disease 0–74 C81
14 Leukaemia 0–44 C91–C95
15 Diseases of the thyroid 0–74 E00–E07
16 Diabetes mellitus 0–49 E10–E14
17 Epilepsy 0–74 G40–G41
18 Chronic rheumatic heart disease 0–74 I05–I09
19 Hypertensive disease 0–74 I10–I13, I15
20 Ischaemic heart disease 0–74 I20–I25
21 Cerebrovascular disease 0–74 I60–I69
22 All respiratory diseases (excl. pneumonia/influenza) 1–14 J00–J09, J20–J99
23 Influenza 0–74 J10–J11
24 Pneumonia 0–74 J12–J18
25 Peptic ulcer 0–74 K25–K27
26 Appendicitis 0–74 K35–K38
27 Abdominal hernia 0–74 K40–K46
28 Cholelithiasis and cholecystitis 0–74 K80–K81
29 Nephritis and nephrosis 0–74 N00–N07, N17–N19, N25–N27
30 Benign prostatic hyperplasia 0–74 N40
31 Maternal deaths 0–74 O00–O99
32 Congenital cardiovascular anomalies 0–74 Q20–Q28
33 Perinatal deaths, all causes excluding stillbirths 0–74 P00–P96, A33, A34
34 Misadventures to patients during surgical and medical care 0–74 Y60–Y69, Y83–Y84
Sources: Causes and codes for causes of death amenable to medical care are taken from Nolte and McKee (2004, 2008) [4, 31].
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(females) were excluded because of missing SEP informa-
tion.
All analyses were stratified by gender and performed using
the statistical software package Stata, version 12.1 for
Windows (StataCorp, College Station, Texas).
Results
Amenable mortality
ASMRs for amenable causes fell from 49.5 (95% CI
48.2–51.0) to 35.7 (34.6–36.9) per 100 000 PYs in males
and from 55.0 (53.6–56.4) to 43.4 (42.2–44.6) per 100 000
PYs in females, when 1996–1998 was compared with
2008–2010 (table 2). For the same time periods, ASMRs
for IHD declined from 64.7 (63.1–66.3) to 33.8
(32.8–34.8) per 100 000 PYs in males and from 18.0
(17.2–18.7) to 8.5 (8.0–9.0) per 100 000 PYs in females.
For non-amenable causes, males showed a decline from
305.2 (301.8–308.6) to 218.7 (216.1–221.4) per 100 000
PYs and females from 137.1 (134.9–139.3) to 112.9
(111.0–114.7). Consequently, all-cause mortality fell from
419.4 (415.4–423.4) to 288.2 (285.2–291.2) per 100 000
PYs in males and from 210.1 (207.4–212.8) to 164.7
(162.5–167.0) per 100 000 PY in females.
Percentage declines in 3-year Swiss ASMRs from 1996
up to and including 2010 were highest for IHD mortality
(47.8% males, 52.9% females) (fig. 1). In males, decreases
were similar for amenable (28.3%) and non-amenable
causes of death (27.8%). In females, amenable mortality
decreased slightly more than non-amenable mortality (21.1
vs 17.7%). Over the entire period all-cause mortality de-
creased by 31.3% in males and 21.6% in females.
However, between 1996–1998 and 2008–2010 the propor-
tion of all-cause mortality attributed to amenable causes re-
mained stable in both sexes (around 12% in males and 26%
in females) with a 2.2-fold higher proportion of amenable
deaths in females (fig. 2). The proportion of IHD mortality
decreased from 15.4 to 11.7% in males and from 8.6 to
5.1% in females. The proportion of deaths attributed to
non-amenable causes increased slightly from 72.8 to
75.9% in males and from 65.3 to 68.5% in females.
In Switzerland 2008-2010, the five leading causes of
amenable death in males were: colorectal cancer ASMR
10.6 (95% CI 10.0–11.2) per 100 000 PYs; cerebrovascu-
lar diseases ASMR 7.8 (7.3–8.3) per 100 000 PYs; perina-
tal deaths ASMR 4.0 (3.6–4.5) per 100 000 PYs; hyperten-
sive diseases ASMR 4.0 (3.7–4.4) per 100 000 PYs; and
pneumonia ASMR 2.5 (2.2–2.8) per 100 000 PYs (see sup-
plementary table S1 in appendix 1). In Swiss females, the
five leading causes of amenable mortality were: breast can-
cer ASMR 18.0 (17.3–18.8) per 100 000 PYs; colorectal
cancer ASMR 6.5 (6.1–6.9) per 100 000 PYs; cerebrovas-
cular diseases ASMR 5.8 (5.4–6.2) per 100 000 PYs; peri-
natal deaths ASMR 4.0 (3.5–4.5) per 100 000 PYs; and hy-
pertensive diseases ASMR 2.2 (2.0–2.5) per 100 000 PYs.
In both sexes, the five leading causes of death accounted
for more than 80% of all amenable deaths.
International comparisons
Compared with 16 other high-income countries, Switzer-
land had the lowest rates of amenable mortality (fig. 3).
Swiss ASMRs were 50.1 (males) and 54.7 (females) per
100 000 PYs in 1997–1998 and 38.6 (males) and 44.0 (fe-
males) per 100 000 PYs in 2006–2007. Switzerland ranks
among the top five countries with the lowest IHD mortality
with ASRMs of 64.4 (males) and 17.7 (females) per
100 000 PYs in 1997–1998 and 37.8 (males) and 9.3 (fe-
males) per 100 000 PYs in 2006–2007 (fig. 4).
Overall international mortality rates of amenable causes,
IHD and non-amenable causes declined substantially be-
tween observation periods. On average, amenable mortal-
ity declined by 28.5% in males (Switzerland 23.0%, sup-
plementary table S2) and by 24.7% in females (Switzer-
land 19.6%, table S3). IHD mortality declined on average
by 40.0% in males (Switzerland 41.2%) and by 44.3%
in females (Switzerland 47.6%). Non-amenable mortality
showed an average decline of 15.8% in males (Switzerland
22.9) and 11.3% in females (Switzerland 11.3%).
Amenable mortality and sociodemographic character-
istics
The SNC analysis dataset included 3 198 927 males and
3 226 604 females, resulting in 24 402 938 PYs in males
and 24 573 021 PYs in females. Overall, 85 773 males and
50 675 females died during follow up: 9604 males and
12 566 females died from amenable causes and 11 490
males and 3456 females from IHD. Non-amenable causes
accounted for 64 679 and 34 653 deaths in males and fe-
males, respectively. Sociodemographic characteristics of
the analysed study population are presented in table 3.
All types of mortality showed increasing hazards with low-
er socioeconomic position (table 4). Adjusted HRs of
Table 2: Three-year age-standardised mortality rates (ASMR) (European standard [32]) per 100 000 person-years, 95% confidence intervals (95% CI), age 0–74 years:
amenable causes, ischaemic heart diseases, non-amenable causes and all causes by sex for the population of Switzerland, time period 1996–2010.
Amenable causes Ischaemic heart diseases Non-amenable causes All causesYear of death
ASMR 95% CI ASMR 95% CI ASMR 95% CI ASMR 95% CI
Males
1996–1998 49.5 48.2–51.0 64.7 63.1–66.3 305.2 301.8–308.6 419.4 415.4–423.4
1999–2001 47.8 46.4–49.2 53.6 52.3–55.1 283.4 280.2–286.7 384.8 381.1–388.6
2002–2004 42.2 40.9–43.5 43.6 42.3–44.8 262.8 259.8–265.9 348.6 345.1–352.1
2005–2007 39.5 38.3–40.7 38.7 37.6–39.9 235.4 232.6–238.2 313.6 310.4–316.9
2008–2010 35.7 34.6–36.9 33.6 32.8–34.8 218.7 216.1–221.4 288.2 285.2–291.2
Females
1996–1998 55.0 53.6–56.4 18.0 17.2–18.7 137.1 134.9–139.3 210.1 207.4–212.8
1999–2001 50.3 48.9– 51.6 14.8 14.1–15.5 132.7 130.6–134.8 197.7 195.1–200.4
2002–2004 48.1 46.8–49.4 11.8 11.2–12.4 127.1 125.1–129.2 187 184.5–189.5
2005–2007 44.3 43.1–45.5 9.7 9.1–10.2 119.6 117.7–121.6 173.6 171.2–176.0
2008–2010 43.4 42.2–44.6 8.5 8.0–9.0 112.9 111.0–114.7 164.7 162.5–167.0
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Figure 1: Percentage changes in 3-year age-standardised mortality rates (European standard [32]), age 0–74 years: amenable causes, is-
chaemic heart diseases (IHD), non-amenable causes and all causes by sex for the population of Switzerland, time period 1996–2010.
Figure 2: Proportion of all-cause mortality attributed to amenable causes, ischaemic heart diseases (IHD) and non-amenable causes based
on 3-year age-standardised mortality rates (European standard [32]), age 0–74 years: by sex for the population of Switzerland, time period
1996–1998 and 2008–2010.
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amenable causes in the lowest Swiss-SEP quintile were
1.77 (95% CI 1.66–1.90) for males and 1.78 (1.47-2.16)
for females as compared with those in the highest quintile.
Compared with the German-speaking region of Switzer-
land, living in the French- and/or Italian-speaking regions
of Switzerland was consistently associated with lower HRs
of amenable and IHD deaths in both sexes, although the
difference was not statistically significant for amenable
deaths in females. Male and female non-Swiss residents
had consistently lower hazards for all types of mortality
ranging from 0.77 (95% CI 0.74–0.79) (non-amenable
deaths in females) to 0.91 (0.86–0.96) (amenable deaths in
males).
Discussion
Levels and trends of amenable mortality
In Switzerland 1996–2010, we found substantial decreases
for all types of mortality. Women showed higher rates
of amenable mortality than males. This result can be ex-
plained by taking a closer look at the distinct conditions
classified as amenable and the individual rates of these
conditions. The higher rate in females is mainly driven
by breast cancer, which contributed more than 40% of all
amenable deaths in Swiss women below the age of 75
years. In addition, IHD rates were considered separately
and, therefore, higher IHD rates in males did not affect pre-
sented rates of amenable mortality.
However, only percentage declines in IHD mortality clear-
ly outweighed reductions in non-amenable and all-cause
mortality. Consequently, the contribution of amenable
mortality to all-cause mortality remained stable, while the
proportion of deaths caused by IHD decreased in both sex-
es. This is surprising, as the literature up to 2004 showed
consistent patterns in time trends, with a more rapid de-
cline of amenable mortality than non-amenable and all-
cause mortality irrespective of differences in the conditions
classified as amenable [4]. This pattern was confirmed by
use of the list of amenable causes of deaths compiled by
Nolte and McKee for 12 European countries and the time
period 1980–1998 [4] and for 16 Western countries com-
paring the time periods 1996–1997 and 2006–2007 [18].
However, the more recent publication counted 50% of IHD
deaths as amenable and included them in the overall num-
ber of amenable deaths, whereas IHD was treated sepa-
rately in the publication of 2004. Nolte and McKee [18]
themselves pointed out that falling amenable mortality in
the more recent publication was driven to some extent by
falling death rates from IHD. Therefore, it seems likely
that large proportions of IHD deaths obscured the changes
in mortality of other causes classified as amenable. In the
context of the current work, figures from the more recent
publication [18] were recalculated to enable an isolated
Figure 3: Age-standardised mortality rates (ASMR) (European standard [32]) per 100 000 person-years of amenable causes by sex for the
population of 17 high-income countries, age 0–74 years, time periods 1997/1998 and 2006/2007.All results in this figure, other than those for
Switzerland, are based on figures published by Nolte and McKee (2011) [18]. Unlike the present study, Nolte and McKee did not treat
amenable causes and ischaemic heart disease (IHD) separately. Instead, 50% of deaths caused by IHD were classified as amenable. Based
on the published figures, the rates of amenable conditions and IHD were recalculated to enable an isolated consideration of amenable and
deaths caused by IHD. For countries with populations <10 million, rates are based on combined years (Austria, Denmark, Finland, Ireland,
New Zealand, Norway, Sweden and Switzerland). For simplicity, this is referred to as combined years, with 1997/1998 as the starting point and
2006/2007 as the end point of the period under review. The sequence reflects the order based on the results of 2006/2007.
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consideration of deaths caused by IHD and to ensure com-
parability of the results. Using the recalculated figures and
the Swiss results, four countries show lower (Denmark,
Netherlands, Switzerland, US) or equal (New Zealand)
percentage decreases for amenable mortality compared
with all-cause mortality in males. These findings may in-
dicate – at least for the male population in some Western
countries – the beginning of changes in time trend patterns.
One possible explanation might be that some Western
countries reached the limits of improvements for at least
some conditions classified as amenable [4, 35]. If IHD
mortality is not taken into account, the Swiss results pre-
dominantly suggest that healthcare did not substantially
contribute, over and above other determinants of popula-
tion health, to continued mortality improvements in the
time-period investigated.
On the basis of the leading causes of amenable deaths
(breast cancer in females, colorectal cancer in males), en-
hancing early cancer detection and quality of cancer care
might probably be most effective in further reducing mor-
tality rates of amenable causes. For example, colorectal
cancer screening prevalence among Swiss residents is low
[36]. For female breast cancer, substantial socioeconomic
inequalities in cancer screening, stage at presentation and
treatment have been observed [37, 38]. These findings
highlight the need to support early cancer detection and
cancer awareness in the general population across all social
groups. For IHD mortality, evidence from outside Switzer-
land suggests that around 50% of all IHD deaths are
amenable to medical care [39]. Assuming a similar propor-
tion for Switzerland, improvements in IHD care should al-
so be a priority area to reduce amenable mortality.
When the Swiss results were compared with 16 Western
countries, Switzerland showed the lowest rates of
amenable mortality. Between 1997–1998 and 2006–2007,
percentage declines for Swiss amenable mortality were
distinctly below those from all included countries. These
comparably low percentage declines may originate in the
already low Swiss baseline levels of amenable mortality
in 1997–1998. For IHD mortality, Switzerland shows per-
centage decreases above average, resulting in comparably
low IHD mortality rates in 2006–2007. All in all, the re-
sults suggest that Switzerland reached a remarkable level
of population health. This is supported by an international-
ly high ranking general [40] and healthy life expectancy of
the Swiss population [41]. However, further Swiss studies
are needed to investigate the actual contribution of health-
care quality to the good results.
Amenable mortality and socioeconomic position
Consistently with the previous literature outside of
Switzerland, this study found substantial socioeconomic
inequalities in amenable mortality [5, 7–9].
Figure 4: Age standardised mortality rates (ASMR) (European standard [32]) per 100 000 person-years for ischaemic heart disease (IHD) by
sex for the population of 17 high-income countries, age 0–74 years, time periods 1997/1998 and 2006/2007.All results in this figure, other than
those for Switzerland, are based on figures published by Nolte and McKee (2011) [18]. Unlike the present study, Nolte and McKee did not treat
amenable causes and ischaemic heart disease (IHD) separately. Instead, 50% of deaths caused by IHD were classified as amenable. Based
on the published figures, the rates of amenable conditions and IHD were recalculated to enable an isolated consideration of amenable and
deaths caused by IHD. For countries with populations <10 million, rates are based on combined years (Austria, Denmark, Finland, Ireland,
New Zealand, Norway, Sweden and Switzerland). For simplicity, this is referred to as combined years, with 1997/1998 as the starting point and
2006/2007 as the end point of the period under review. The sequence reflects the order based on the results of 2006/2007.
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Table 3: Sociodemographic characteristics of the study population at
census 2000, age 0–74 years: Swiss National Cohort (SNC).
Males Females




538 215 16.8% 558 258 17.3%
Quintile 4 599 524 18.7% 614 895 19.1%
Quintile 3 619 378 19.4% 629 534 19.5%
Quintile 2 652 032 20.4% 654 222 20.3%
Quintile 1 (lowest
SEP)
789 778 24.7% 769 695 23.9%
Language regions
German 2 320 080 72.5% 2 319 457 71.9%
French 739 592 23.1% 761 905 23.6%
Italian 139 255 4.4% 145 242 4.5%
Nationality
Swiss 2 470 355 77.2% 2 593 872 80.4%
Non-Swiss 728 572 22.8% 632 732 19.6%
Age at census
(years)
0–14 584 598 18.3% 557 153 17.3%
15–39 1 226 154 38.3% 1 213 223 37.6%
40–64 1 135 584 35.5% 1 143 686 35.5%
65–74 252 591 7.9% 312 542 9.7%
Total 3 198 927 100.0% 3 226 604 100.0%
Swiss-SEP: area-based index of Swiss socioeconomic position (SEP)
An international study on socioeconomic inequalities of
amenable mortality undertaken by Plug et al. [7], found
substantial social inequalities in amenable and non-
amenable mortality for Switzerland and the other coun-
tries/regions included in the study [7]. Plug et al. [7] also
presented Swiss results 1990–2000 based on the SNC. Un-
like in the present study, socioeconomic position was de-
fined by level of education, the investigation was based
on the 1990 census, the selected conditions classified as
amenable were based on an updated version of the original
list of Rutstein et al. [2], and data were not stratified by
gender. Plug et al. [7] also investigated whether inequali-
ties in mortality are associated with inequalities in behav-
ioural risk factors and/or medical use (used as proxy for
healthcare access). They found no evidence that inequal-
ities in amenable mortality are more strongly associated
with differences in medical use than non-amenable mor-
tality, arguing against a substantial association between
amenable mortality and medical use and/or healthcare
quality [7]. Overall, Plug et al. concluded that inequalities
in amenable mortality might be caused by the same risk
factors as those involved in non-amenable causes.
In summary, the present study detected substantial socioe-
conomic inequalities for amenable mortality and non-
amenable mortality in Switzerland. Further investigations
are needed to identify whether inequalities in amenable
mortality are attributable to inequalities in medical use
and/or healthcare quality.
Table 4: Hazard ratios of deaths and 95% confidence intervals (95% CI), age 0–74 years: amenable causes, ischaemic heart diseases and non-amenable causes by sex for the
population of Switzerland at census 2000, followed until death, migration or the end of 2008.
Amenable causes Ischaemic heart diseases Non-amenable causes
Hazard ratio 95% CI Hazard ratio 95% CI Hazard ratio 95% CI
Males
Swiss-SEP index
Quintile 5 (highest SEP) 1.00 1.00 1.00
Quintile 4 1.26 1.17–1.35 1.29 1.21–1.38 1.20 1.17–1.23
Quintile 3 1.52 1.42–1.63 1.44 1.35–1.54 1.35 1.31–1.38
Quintile 2 1.61 1.51–1.73 1.63 1.53–1.73 1.45 1.42–1.49
Quintile 1 (lowest SEP) 1.77 1.66–1.90 1.76 1.66–1.87 1.62 1.58–1.66
Language region
German 1.00 1.00 1.00
French 0.91 0.87–0.96 0.68 0.65–0.72 1.10 1.08–1.12
Italian 0.85 0.78–0.94 0.85 0.78–0.92 0.97 0.93–1.00
Nationality
Swiss 1.00 1.00 1.00
Non-Swiss 0.91 0.86–0.96 0.80 0.76–0.85 0.81 0.79–0.82
Females
Swiss-SEP index
Quintile 5 (highest SEP) 1.00 1.00 1.00
Quintile 4 1.25 1.02–1.55 1.54 1.36–1.75 1.13 1.09–1.17
Quintile 3 1.60 1.31–1.95 1.72 1.52–1.95 1.19 1.15–1.24
Quintile 2 1.55 1.27–1.90 1.98 1.75–2.23 1.28 1.23–1.32
Quintile 1 (lowest SEP) 1.78 1.47–2.16 2.33 2.07–2.62 1.38 1.33–1.43
Language region
German 1.00 1.00 1.00
French 0.92 0.80–1.06 0.62 0.57–0.68 1.01 0.98–1.03
Italian 0.86 0.65–1.13 0.58 0.48–0.69 0.86 0.81–0.90
Nationality
Swiss 1.00 1.00 1.00
Non-Swiss 0.85 0.69–1.05 0.85 0.75–0.96 0.77 0.74–0.79
All models were adjusted for all sociodemographic variables listed above. The models were adjusted for age by using age as time-scale. To control for birth cohort and/or period
effects, the models were stratified on 5-year birth cohorts. Swiss-SEP index: area-based index of Swiss socioeconomic position (SEP)
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Amenable mortality and language region
Living in the French- and/or Italian-speaking regions of
Switzerland was associated with a reduced risk of dying
from amenable causes or IHD as compared with living
in the German-speaking region. Differences in the provi-
sion and quality of medical care may account for this re-
sult, although variations in incidence and/or disease sever-
ity among language regions should also be considered. As
mentioned previously, in Switzerland healthcare services
are organised at the cantonal level [42, 43]. For exam-
ple, organised mammography screening programmes are
currently available in only 50% of the Swiss cantons. In
the cantons with organised mammography screening pro-
grammes, organised and opportunistic screening coexist,
and distribution of organised versus opportunistic screen-
ing varies substantially across regions [44, 45]. For car-
diovascular diseases, Marques-Vidal and Paccaud [26] ob-
served substantial regional differences in self-reported risk
factors, screening and disease management in Switzerland.
Self-reported screening for diabetes, for example, was
highest in the Italian-speaking region of Switzerland,
whereas the lowest treatment rates in patients with high
cholesterol levels and/or diabetes were observed in the
German-speaking region of Switzerland. However, as
mentioned above (parts of) the observed mortality differ-
ences may also reflect differences in underlying incidence
rates rather than differences in the quality of medical care.
This assumption is supported by the variation in IHD mor-
bidity [46, 47] in Switzerland’s neighbouring countries
(higher in Germany and Austria compared with Italy and
France) and the cultural orientation (e.g., lifestyle, dietary
habits) of the language regions towards their neighbouring
country with the corresponding language.
Amenable mortality and nationality
Compared with male and female Swiss citizens, non-citi-
zens showed reduced hazards for all types of death. One
potential explanation for this might be the so-called
“healthy migrant effect”. The healthy migrant effect de-
scribes an empirically observed mortality advantage of mi-
grants relative to the population in the host country. This
observation is usually explained as a preselection of
healthy individuals at time of immigration, leading to bet-
ter health outcomes in spite of potential social inequalities
and discrimination. In this study, data quality issues might
have affected nationality results. Death records of non-
Swiss nationals showed an increased probability of not be-
ing linked to census data as compared with death records
of Swiss nationals [19]. In addition, undocumented out-
migration may have led to incomplete mortality follow-up
[48].
The non-Swiss population is made of highly heterogeneous
groups according to country of origin, migration status
(first, second or third generation immigrants), type of resi-
dence permit, level of education, employment and income,
to name a few. A supplementary analysis (not presented
but available upon request) detected substantial variations
in mortality between groups of nationalities even after ad-
justing for Swiss-SEP and other sociodemographic charac-
teristics. Hence, this topic should be investigated further in
future studies with particular regard to potential sources of
bias. This is particularly important since there is a paucity
of data on the health of immigrants or foreign nationals in
Switzerland.
Strengths and limitations
The study is the first detailed population-based investiga-
tion of the effectiveness of healthcare in Switzerland with
use of amenable mortality as quality indicator. We exam-
ined time trends of amenable mortality, the association
between sociodemographic characteristics and amenable
mortality and provided an international framework for the
Swiss results.
There are some limitations in amenable mortality as a mea-
sure of the quality of medical care. In particular, stud-
ies investigating the association between amenable mor-
tality and healthcare inputs have produced mixed findings
and failed to identify strong and consistent relationships
[3, 4, 29]. Therefore, the usefulness of amenable mortality
as an indicator of the quality of medical care has been
questioned [49–51]. However, most of these studies have
looked at resources or supply of health services (e.g. per-
centage of gross domestic product spent on health services,
number of healthcare professionals, hospitals or hospital
beds per defined population, etc.) rather than quality mea-
surements (e.g., effectiveness of healthcare services) [3, 4].
Furthermore, health expenditures may be affected by lev-
el of incidence and/or mortality rates, as resources may be
diverted according to the specific needs of certain regions
[29]. Our study did not include healthcare supply mea-
sures. However, the Swiss results can be interpreted as in-
direct evidence arguing predominantly against a strong as-
sociation between amenable mortality and healthcare qual-
ity.
In addition, amenable mortality “is not a definitive source
of evidence of differences in effectiveness of health care”
[4]. Rather it is an indicator for estimating potential weak-
nesses and strengths of medical care that can or should be
investigated in more depth, in the case of conspicuous re-
sults [4]. Moreover, mortality is affected by various factors
outside the scope of the healthcare services. To identify un-
derlying mechanisms and the contribution of components
of the Swiss healthcare system, further research is needed.
Time trends and regional differences in amenable mortality
might be affected by simultaneous changes in disease inci-
dence or severity of disease at diagnosis [3, 4]. Some au-
thors addressed this potential limitation and concluded that
incidence-adjusted mortality rates are likely to enhance
amenable mortality as quality indicator of healthcare sys-
tems [52, 53]. However, other authors have suggested that
rates of amenable mortality should not be adjusted for inci-
dence or severity at presentation since they are part of the
population health needs and are within the responsibility of
the healthcare services [54–57]. Further, precise Swiss in-
cidence figures are not available for all conditions classi-
fied as amenable. However, it has been shown that differ-
ences in amenable mortality cannot simply be explained by
variations in disease incidence [4].
Another point of criticism focuses on the variation of caus-
es of deaths that were considered amenable by the various
researchers and somewhat arbitrary age limits used to clas-
sify deaths as amenable. In this study, we used the version
compiled by Nolte and McKee [4] which is based on an an-
notated review of the work that has been conducted world-
wide and has been used by various researchers since its
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publication in 2004 [3, 28, 30, 58–60]. However, every list
of causes of death considered as amenable is to some ex-
tent dependent on the view of the respective researcher(s)
who developed it.
Finally, the concept of amenable mortality uses cause of
death certification as data source. Observed differences at
country or regional level and over time may be – at least
partly – due to dissimilarities in diagnostic patterns for
death certification or differences in coding practices of the
underlying causes of death [4, 61, 62].
Conclusion
Amenable mortality constitutes a substantial proportion of
all-cause mortality in Switzerland. As in other developed
countries, amenable mortality declined substantially be-
tween 1996 and 2010. However, the proportion of all-cause
mortality attributed to amenable causes remained stable. In
contrast to other countries Switzerland showed compara-
bly low death rates for amenable causes and IHD.
Similarly to previous international studies, these Swiss re-
sults showed substantial socioeconomic inequalities in
amenable mortality. Unexpectedly, proportions of
amenable mortality remained constant over time. Addi-
tional amenable mortality research is needed to better un-
derstand the factors contributing to inequalities and
changes over time including information on disease char-
acteristics and health care supply measures. In future Swiss
research, in-depth studies should investigate cantonal/re-
gional variations in the mortality declines and its associ-
ation with cantonal/regional disparities in healthcare pro-
vision and/or utilisation. Further, the concept of amenable
mortality should be adapted to the Swiss health profile by
taking national or regional incidence trends into account.
Finally, observed socioeconomic inequalities should be as-
sessed in more detail (e.g., by cause of death, region, etc.).
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Appendix 1 Supplementary tables
Table S1: Three-year age-standardised mortality rates (European standard [32]) per 100 000 person-years, 95% confidence intervals, age 0–74 years: cause-specific amenable
mortality by sex for the population of Switzerland, time periods 1996–1998 and 2008–2010.
Cause of death 1996–1998 2008–2010
Male Female Male Female
ASMR (Euro) 95% CI ASMR (Eu-
ro)
95% CI ASMR (Eu-
ro)
95% CI ASMR (Eu-
ro)
95% CI
Intestinal infections 0.03 0.00–0.09 0.00 0.00–0.04 0.01 0.00–0.07 0.01 0.00–0.07




0.00 0.00–0.04 0.00 0.00–0.04 0.00 0.00–0.04 0.01 0.00–0.06
Whooping cough 0.00 0.00–0.04 0.03 0.00–0.09 0.00 0.00–0.04 0.02 0.00–0.07
Septicaemia 1.20 0.99–1.43 0.63 0.49–0.79 0.87 0.72–1.06 0.45 0.34–0.59
Measles 0.00 0.00–0.04 0.00 0.00–0.04 0.00 0.00–0.04 0.00 0.00–0.04
Colorectal cancer 13.26 12.56–13.99 7.69 7.19–8.22 10.59 10.03–11.18 6.49 6.06–6.94
Skin cancer 0.31 0.21–0.44 0.19 0.12–0.29 0.25 0.17–0.36 0.16 0.10–0.25
Breast cancer 0.15 0.08–0.24 22.51 21.63–23.43 0.10 0.05–0.18 18.04 17.32–18.79
Cancer of the cervix uteri n.a. – 1.83 1.59–2.11 n.a. – 1.08 0.91–1.28
Cancer of cervix uteri
and body of the uterus
n.a. – 0.05 0.02–0.12 n.a. – 0.04 0.01–0.10
Malignant neoplasm of
testis
0.33 0.23–0.46 n.a. – 0.23 0.15–0.34 n.a. –
Hodgkin's disease 0.34 0.24–0.48 0.20 0.12–0.30 0.33 0.23–0.45 0.27 0.18–0.38
Leukaemia 0.85 0.68–1.05 0.61 0.46–0.78 0.49 0.36–0.64 0.30 0.20–0.43
Diseases of the thyroid 0.04 0.01–0.10 0.11 0.06–0.19 0.03 0.01–0.09 0.03 0.01–0.09
Diabetes mellitus 0.60 0.46–0.76 0.25 0.16–0.36 0.39 0.29–0.52 0.22 0.15–0.33
Epilepsy 1.04 0.85–1.26 0.74 0.58–0.93 0.82 0.67–1.01 0.55 0.42–0.70
Chronic rheumatic heart
disease
0.40 0.29–0.54 0.35 0.25–0.48 0.16 0.10–0.25 0.27 0.19–0.38
Hypertensive disease 3.94 3.56–4.35 2.30 2.04–2.59 3.99 3.65–4.36 2.20 1.96–2.46




0.07 0.03–0.16 0.07 0.02–0.15 0.02 0.00–0.08 0.03 0.00–0.09
Influenza 0.30 0.20–0.43 0.21 0.13–0.31 0.04 0.01–0.11 0.03 0.01–0.08
Pneumonia 3.09 2.76–3.45 1.60 1.38–1.85 2.47 2.20–2.77 1.25 1.06–1.46
Peptic ulcer 0.76 0.60–0.95 0.52 0.40–0.67 0.45 0.34–0.58 0.27 0.19–0.38
Appendicitis 0.06 0.02–0.14 0.07 0.03–0.15 0.04 0.01–0.10 0.03 0.01–0.08
Abdominal hernia 0.17 0.10–0.28 0.11 0.06–0.19 0.15 0.09–0.24 0.13 0.08–0.21
Cholelithiasis and chole-
cystitis
0.22 0.13–0.33 0.13 0.07–0.21 0.21 0.14–0.31 0.12 0.07–0.20
Nephritis and nephrosis 1.10 0.91–1.33 0.78 0.63–0.95 1.00 0.83–1.19 0.53 0.41–0.67
Benign prostatic hyper-
plasia
0.07 0.03–0.14 n.a. – 0.04 0.01–0.09 n.a. –
Maternal deaths n.a. – 0.08 0.04–0.16 n.a. – 0.12 0.07–0.21
Congenital cardiovascu-
lar anomalies
2.01 1.71–2.34 1.41 1.16–1.69 1.09 0.88–1.34 0.87 0.68–1.10
Perinatal deaths (excl.
stillbirths)
3.90 3.47–4.37 3.10 2.70–3.53 4.01 3.56–4.49 3.97 3.51–4.47
Misadventures to pa-
tients during surgical and
medical care
0.03 0.01–0.09 0.06 0.02–0.13 0.07 0.03–0.14 0.02 0.00–0.07
ASMR = age-standardised mortality rate; CI = confidence interval; n.a. = not applicable The classification and sequence of causes of death correspond to the conditions listed
in table 1, with the exception of ischaemic heart disease mortality, which has been already analysed separately in table 2.
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Table S2: Age-standardised mortality rates (European standard [32]) per 100 000 person-years and percentage changes in the male population of 17 high income countries,





Change 1997/1998 – 2006/2007










Am. (%) IHD (%) Non-am
(%)
All (%)
Australia 58.6 81.6 272.6 412.9 14.2 19.8 40.7 43.2 213.8 297.7 13.7 14.5 ˗30.6 ˗47.0 ˗21.6 ˗27.9
Austria 78.6 107.2 328.7 514.5 15.3 20.8 50.0 58.5 278.9 387.4 12.9 15.1 ˗36.4 ˗45.4 ˗15.1 ˗24.7
Denmark 77.4 86.9 383.5 547.8 14.1 15.9 63.5 40.7 337.6 441.8 14.4 9.2 ˗18.0 ˗53.1 ˗12.0 ˗19.3
Finland 80.8 139.1 341.9 561.8 14.4 24.8 49.5 86.4 317.9 453.9 10.9 19.0 ˗38.7 ˗37.9 ˗7.0 ˗19.2
France 65.5 40.7 397.3 503.6 13.0 8.1 47.3 27.3 327.0 401.6 11.8 6.8 ˗27.8 ˗32.9 ˗17.7 ˗20.2
Germany 77.0 96.6 343.6 517.2 14.9 18.7 57.0 60.9 289.2 407.1 14.0 15.0 ˗26.0 ˗36.9 ˗15.8 ˗21.3
Greece 72.6 81.5 298.7 452.8 16.0 18.0 57.0 72.4 269.2 398.6 14.3 18.2 ˗21.5 ˗11.1 ˗9.9 ˗12.0
Ireland 85.1 144.9 322.3 552.4 15.4 26.2 47.0 76.2 250.5 373.8 12.6 20.4 ˗44.7 ˗47.4 ˗22.3 ˗32.3
Italy 70.5 61.5 321.3 453.2 15.5 13.6 46.7 36.2 244.6 327.4 14.3 11.1 ˗33.8 ˗41.1 ˗23.9 ˗27.8
Japan 88.0 27.2 277.0 392.2 22.4 6.9 63.4 23.2 238.5 325.1 19.5 7.1 ˗28.0 ˗14.8 ˗13.9 ˗17.1
Netherlands 66.9 78.3 322.2 467.4 14.3 16.8 49.3 34.6 256.3 340.2 14.5 10.2 ˗26.3 ˗55.8 ˗20.5 ˗27.2
New
Zealand
70.5 112.0 289.2 471.7 15.0 23.7 52.5 65.8 232.9 351.1 14.9 18.7 ˗25.6 ˗41.3 ˗19.5 ˗25.6
Norway 66.3 98.5 286.6 451.3 14.7 21.8 46.3 45.8 239.5 331.6 14.0 13.8 ˗30.2 ˗53.5 ˗16.4 ˗26.5
Sweden 57.8 93.9 245.2 396.9 14.6 23.7 40.0 55.1 216.4 311.5 12.8 17.7 ˗30.8 ˗41.3 ˗11.7 ˗21.5
Switzerland 50.1 64.4 299.9 414.4 12.1 15.5 38.6 37.8 231.2 307.7 12.5 12.3 ˗23.0 ˗41.2 ˗22.9 ˗25.7
UK 81.7 126.1 284.3 492.1 16.6 25.6 56.8 68.9 253.8 379.5 15.0 18.2 ˗30.5 ˗45.3 ˗10.7 ˗22.9
USA 79.8 113.6 358.6 552.0 14.5 20.6 69.7 74.4 328.2 472.3 14.8 15.7 ˗12.7 ˗34.5 ˗8.5 ˗14.4
Average 72.2 91.4 316.1 479.6 15.1 18.8 51.5 53.4 266.2 371.1 13.9 14.3 ˗28.5 ˗40.0 ˗15.8 ˗22.7
Am. = amenable causes; All = all causes; IHD = ischaemic heart disease; Non-am. = non-amenable causes All results in this table, other than those for Switzerland, are based on
figures published by Nolte and McKee (2011) [18]. Unlike the present study, Nolte and McKee did not treat amenable causes and IHD separately. Instead, 50% of deaths caused
by IHD were classified as amenable. Based on the published figures, the rates of amenable conditions and IHD were recalculated to enable an isolated consideration of amenable
and deaths caused by IHD. For countries with populations <10 million, rates are based on combined years (Austria, Denmark, Finland, Ireland, New Zealand, Norway, Sweden
and Switzerland). For simplicity, this is referred to as combined years, with 1997/1998 as the starting point and 2006/2007 as the end point of the period under review.
Table S3: Age-standardised mortality rates (European standard) per 100 000 person-years and percentage changes in the female population of 17 high income countries, age





Change 1997/1998 – 2006/2007










Am. (%) IHD (%) Non-am
(%)
All (%)
Australia 62.5 28.3 135.7 226.4 27.6 12.5 45.2 12.8 116.0 174.1 26.0 7.4 ˗27.7 ˗54.6 ˗14.5 ˗23.1
Austria 70.3 33.5 141.3 245.0 28.7 13.7 48.3 15.7 128.5 192.4 25.1 8.1 ˗31.3 ˗53.2 ˗9.0 ˗21.5
Denmark 90.3 30.3 232.8 353.3 25.5 8.6 68.8 15.3 195.1 279.3 24.6 5.5 ˗23.7 ˗49.3 ˗16.2 ˗20.9
Finland 65.7 36.1 141.7 243.5 27.0 14.8 45.8 19.5 132.6 197.9 23.2 9.8 ˗30.2 ˗46.0 ˗6.4 ˗18.7
France 61.1 9.7 144.6 215.3 28.4 4.5 46.6 5.7 126.9 179.1 26.0 3.2 ˗23.8 ˗41.2 ˗12.3 ˗16.8
Germany 72.0 32.0 152.8 256.9 28.0 12.5 56.7 18.4 133.1 208.2 27.2 8.9 ˗21.4 ˗42.4 ˗12.9 ˗19.0
Greece 70.0 23.1 129.9 223.0 31.4 10.4 51.6 17.6 105.9 175.1 29.5 10.1 ˗26.3 ˗23.6 ˗18.5 ˗21.5
Ireland 87.4 48.2 175.6 311.1 28.1 15.5 59.6 21.8 143.0 224.4 26.6 9.7 ˗31.8 ˗54.8 ˗18.6 ˗27.9
Italy 68.5 17.2 133.4 219.1 31.2 7.9 50.1 10.4 108.6 169.1 29.6 6.2 ˗26.9 ˗39.6 ˗18.6 ˗22.9
Japan 57.6 8.9 112.4 178.9 32.2 5.0 44.6 6.8 97.1 148.5 30.0 4.6 ˗22.6 ˗23.5 ˗13.6 ˗17.0
Nether-
lands
74.7 26.5 158.4 259.6 28.8 10.2 58.5 12.1 146.6 217.2 26.9 5.6 ˗21.7 ˗54.3 ˗7.4 ˗16.3
New
Zealand
84.8 36.2 164.3 285.3 29.7 12.7 61.9 20.5 148.2 230.7 26.8 8.9 ˗27.0 ˗43.3 ˗9.8 ˗19.1
Norway 68.6 27.1 146.8 242.5 28.3 11.2 51.6 13.0 138.9 203.6 25.4 6.4 ˗24.7 ˗52.0 ˗5.3 ˗16.0
Sweden 58.4 28.3 138.0 224.6 26.0 12.6 46.4 17.2 130.8 194.4 23.9 8.9 ˗20.5 ˗39.1 ˗5.2 ˗13.4
Switzer-land 54.7 17.7 135.4 207.8 26.3 8.5 44.0 9.3 120.2 173.4 25.4 5.3 ˗19.6 ˗47.6 ˗11.3 ˗16.6
UK 86.2 45.2 167.3 298.7 28.9 15.1 63.3 21.6 153.8 238.8 26.5 9.1 ˗26.6 ˗52.1 ˗8.1 ˗20.1
USA 81.6 45.8 201.2 328.7 24.8 13.9 70.0 29.0 191.5 290.5 24.1 10.0 ˗14.3 ˗36.6 ˗4.8 ˗11.6
Average 71.4 29.1 153.6 254.1 28.3 11.1 53.7 15.7 136.3 205.7 26.3 7.5 ˗24.7 ˗44.3 ˗11.3 ˗19.0
Am. = amenable causes; All = all causes; IHD = ischaemic heart disease; Non-am. = non-amenable causes All results in this table, other than those for Switzerland, are based on
figures published by Nolte and McKee (2011) [18]. Unlike the present study, Nolte and McKee did not treat amenable causes and IHD separately. Instead, 50% of deaths caused
by IHD were classified as amenable. Based on the published figures, the rates of amenable conditions and IHD were recalculated to enable an isolated consideration of amenable
and deaths caused by IHD. For countries with populations <10 million, rates are based on combined years (Austria, Denmark, Finland, Ireland, New Zealand, Norway, Sweden
and Switzerland). For simplicity, this is referred to as combined years, with 1997/1998 as the starting point and 2006/2007 as the end point of the period under review.
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